Manufacturing process development for microbial expression of griffithsin

Active Awarded Last action

Contract number
75N91021F00009
Awardee
Awarding agency
Obligated
$2,123,721

Award facts

Contract value 100% obligated
$2,123,721.00 Current and potential, with all options
Completion date 85% complete
Current and potential, with all options
Funding agency
National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21703, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00015 $0
Other Administrative Action P00014 $0
Other Administrative Action P00013 $0
Change Order P00012 $0
Change Order P00011 $0
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $101,191
Other Administrative Action P00001 $0
Original award $2,022,530
Show all 16

About this award

Written by GovTribe AI ·

The National Center for Advancing Translational Sciences awarded a $2.12 million cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc. for manufacturing process development for microbial expression of griffithsin. The contract, awarded on September 17, 2021, with an ultimate completion date of September 16, 2027, will be performed in Frederick, Maryland. This delivery order was issued without a set-aside designation, reflecting the contractor's competitive capabilities in biomedical research and development. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., operates as a Federally Funded Research and Development Center contractor primarily supporting the National Cancer Institute and National Institutes of Health with comprehensive biomedical research and facilities support services.

The work involves developing manufacturing processes for griffithsin, a protein therapeutic candidate with potential antiviral applications, through microbial expression systems. This contract aligns with NCATS's translational science mission to accelerate the development of medical therapies and demonstrates Leidos Biomedical Research's established expertise in manufacturing therapeutic agents and supporting advanced research initiatives across federal health agencies. The cost-plus-fixed-fee structure and extended performance period reflect the development nature of the work and the technical complexity associated with optimizing microbial expression systems for pharmaceutical manufacturing.

Quick answers

Who was awarded contract 75N91021F00009?

75N91021F00009 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 17, 2021.

How much is contract 75N91021F00009 worth?

The government has obligated $2,123,721 on 75N91021F00009.

Which agency awarded contract 75N91021F00009?

National Cancer Institute (National Institutes of Health) awarded 75N91021F00009, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).

Is contract 75N91021F00009 an order under another contract?

Yes. 75N91021F00009 is a delivery order under 75N91019D00024, an indefinite delivery contract.

Was contract 75N91021F00009 competed?

The extent of competition for 75N91021F00009 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login